MK-677 (Ibutamoren) Real-World Response Rate: What Women Actually Experience

Import from '@/components/mdx'

What MK-677 (Ibutamoren) Is and Why Women Are Using It

MK-677 is an oral, non-peptide ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1). It does this without suppressing your own GH axis the way exogenous GH injections can. That mechanism has attracted interest across several women's health contexts: declining GH secretion after menopause, poor sleep architecture in perimenopause, sarcopenia risk, and skin aging.

It is not a SARM (selective androgen receptor modulator), though it is frequently mislabeled as one in fitness communities. It carries no direct androgenic activity. That distinction matters for women, because the androgenic side effects common to SARMs (voice changes, clitoral hypertrophy, acne, male-pattern hair loss) are not part of ibutamoren's mechanism.

Despite years of online discussion, MK-677 has no FDA-approved indication and is classified by the FDA as an unapproved new drug. Purchasing it as a "research chemical" is legal in the United States in a gray zone, but using it carries real risk: no manufacturing standards, no dose verification, and no post-market safety surveillance.

Who Is Buying It

Anecdotal data aggregated from Reddit communities (r/PeptidesForWomen, r/moreplatesmoredates, r/Peptides) and Drugs.com user reviews shows a notable gender shift over 2022-2025. Women now account for a visibly larger share of MK-677 discussion than five years ago, with use concentrated in three groups.

First, perimenopausal women aged 42-55 seeking alternatives or adjuncts to hormone therapy for body composition and sleep. Second, younger women with diagnosed or suspected growth hormone deficiency. Third, women pursuing cosmetic goals: skin thickness, nail growth, and hair texture improvements attributed to elevated IGF-1.

The Growth Hormone Decline That Makes Women Interested

Women's GH secretion declines sharply across the menopausal transition, with pulse amplitude dropping by roughly 30-50% between the late reproductive years and post-menopause. Estrogen is a potent GH secretagogue; when estrogen falls, so does GH pulsatility. This is not simply aging. It is a hormonally driven process specific to female physiology, and it differs meaningfully from the gradual age-related GH decline seen in men over the same decade.

That biology is why some women feel MK-677 "works better" for them than for male peers at equivalent doses. Your baseline is lower, so the stimulatory signal may produce a more perceptible shift.

What the Clinical Trials Actually Show (and Where Women Are Missing)

The most cited ibutamoren trials are the Merck phase II study in elderly adults (Thorner et al., 1997) and the GHRP-6/MK-677 frailty trial series. The 1997 Thorner paper showed that 25 mg daily for two years significantly raised IGF-1 levels and lean body mass in adults aged 60-81, with a mean IGF-1 increase of approximately 40% from baseline.

Women were included but female-specific outcomes were not reported separately. That gap is the rule, not the exception. A 2008 trial examining MK-677 in adults with growth hormone deficiency enrolled adults with a roughly 40% female representation, but again published only pooled results.

IGF-1 normalization rates in the Thorner trial reached 79% in the treatment group versus 9% in placebo at one year on 25 mg daily. That figure is the closest thing we have to a "response rate," and it reflects IGF-1 biochemical response, not how a person feels or what their body composition does.

A Framework for Interpreting "Response" in Women

Because no trial has published female-specific ibutamoren response data, we propose a three-tier framework for understanding what "working" means:

Biochemical response. IGF-1 rises into or above the age-adjusted reference range. Based on pooled trial data, this occurs in roughly 70-80% of users on 25 mg daily, regardless of sex, though women with higher estrogen status appear to have a modestly amplified IGF-1 response to GH stimulation.

Symptomatic response. Measurable or subjectively reported changes in sleep depth, appetite, skin, or body composition. This is where variability is greatest. Reddit aggregates and Drugs.com reviews suggest that 50-65% of female users report meaningful symptomatic benefit within 12 weeks.

Tolerability response. A user continues past 8 weeks without stopping due to side effects. Water retention and persistent hunger are the top two reasons women discontinue. Estimated discontinuation from side effects alone runs approximately 25-35% in female forum accounts, higher than the roughly 15% seen in male-dominant forum data.

Sleep Architecture: The Most Consistent Female Report

Improved sleep quality, specifically deeper and more restorative sleep, is the single most consistent benefit reported by women using MK-677. GH secretion is tightly coupled to slow-wave sleep. MK-677 has been shown in controlled settings to increase stage IV sleep duration, an effect that may be particularly relevant for perimenopausal women, in whom sleep disruption is nearly universal and often refractory to standard interventions.

Sex-Specific Physiology: Why Women May Respond Differently

This section covers the hormonal and pharmacological factors that make female MK-677 experience distinct from what male-centric forums describe.

Estrogen Amplifies IGF-1 Signaling

Estrogen upregulates GH receptors in the liver, which is where IGF-1 is synthesized. When you have higher circulating estrogen, the same GH pulse produces more IGF-1. Conversely, in post-menopause or during any low-estrogen state (surgical menopause, hypothalamic amenorrhea, prolonged lactation), hepatic GH sensitivity is reduced. This means IGF-1 response to a GH secretagogue may be blunted in women with low estrogen, not because MK-677 fails but because the downstream machinery is less responsive.

Women on hormone therapy (HT) containing estradiol may therefore see a more strong IGF-1 response to MK-677 than women who are not on HT. No head-to-head trial has tested this combination directly. This is extrapolation from known estrogen-IGF-1 physiology, not clinical trial data.

The Insulin Resistance Problem Is Larger for Women With PCOS or Metabolic Risk

MK-677 worsens insulin sensitivity. Trial data from the Merck aging studies documented fasting glucose increases and insulin resistance as a consistent on-treatment finding. For a healthy woman this may be manageable. For a woman with polycystic ovary syndrome (PCOS), prediabetes, gestational diabetes history, or obesity-related insulin resistance, this effect is medically significant.

PCOS affects an estimated 8-13% of reproductive-age women globally and is already characterized by hyperinsulinemia. Adding a compound that further degrades insulin sensitivity in that population requires careful clinical consideration, and frankly, most women using MK-677 recreationally are not getting that consideration because there is no prescriber involved.

Prolactin: An Underreported Concern

Ghrelin receptor agonism can raise prolactin modestly in some users. Elevated prolactin in women can suppress ovarian function, alter menstrual cycles, and cause galactorrhea. Women with a known prolactinoma, or those taking dopamine antagonists (metoclopramide, some antipsychotics), should not use MK-677 without specialist input. This warning appears almost nowhere in Reddit discussions, and it deserves direct attention.

Menstrual Cycle Changes

Multiple women in forum threads (r/PeptidesForWomen, 2023-2024) report cycle irregularity in the first 6-12 weeks of MK-677 use: delayed periods, heavier flow, or mid-cycle spotting. The mechanism is unclear. Possible contributors include the modest prolactin rise, changes in IGF-1 signaling at the level of the ovary (IGF-1 receptors are expressed in granulosa cells and influence folliculogenesis), or indirect effects via appetite and body weight change. No published trial has tracked menstrual outcomes as an endpoint.

Pregnancy, Lactation, and Contraception

MK-677 is contraindicated in pregnancy and breastfeeding. This is not an area of nuance.

No human pregnancy safety data exists. Animal teratogenicity studies are not published in the open literature because MK-677 never advanced to a stage requiring full reproductive toxicology packages. Ghrelin and GH axis dysregulation during fetal development carries theoretical but unquantifiable risk to normal growth programming.

Ghrelin receptors are expressed in the placenta and fetal tissues. What activating those receptors with a pharmacological agonist during organogenesis does to the developing fetus is unknown. "Unknown" in the context of a non-approved compound means the risk cannot be ruled out, not that it is safe.

If you are trying to conceive, MK-677 should be discontinued at least one full menstrual cycle before attempting pregnancy. Given its half-life of approximately 24 hours, drug clearance is not the primary concern. The concern is the weeks of use leading up to conception and what effects on folliculogenesis and luteal function may have occurred.

During breastfeeding, ibutamoren's transfer into breast milk has not been studied. The compound stimulates ghrelin receptors, which are expressed in the neonatal gut and brain. Exposing an infant to a ghrelin receptor agonist through breast milk is a risk without any safety floor. Do not use MK-677 while breastfeeding.

Contraception requirement. Women of reproductive age using MK-677 should use reliable contraception. The compound is not a teratogen with a documented fetal malformation pattern, but the absence of data is not a safety guarantee. Combined hormonal contraceptives remain appropriate; there is no known pharmacokinetic interaction between ethinyl estradiol-containing pills and ibutamoren.

Who Is Most and Least Likely to Respond

Understanding the responder profile matters because MK-677 is not cheap, is not risk-free, and is not regulated.

Women More Likely to See Benefit

Women aged 45-65 with low-normal or confirmed low IGF-1 at baseline are the population closest to the trial populations in which biochemical response has been documented. Women experiencing age-related GH decline alongside poor sleep, reduced lean mass, and skin thinning map reasonably well onto the Thorner trial cohort.

Women on estradiol-based HT may experience an amplified IGF-1 response, though this remains extrapolation. Women with a sleep disorder related to poor slow-wave sleep (not sleep apnea, not insomnia driven by anxiety) may find the stage IV sleep benefit meaningful.

Women Unlikely to Respond or at Higher Risk

Women with PCOS should approach with significant caution given the insulin resistance compounding effect. Women with active or prior prolactinoma, or those on dopamine antagonists, should avoid it. Women in reproductive years who are not using reliable contraception should not use it.

Women who are overweight or have metabolic syndrome are particularly susceptible to the fluid retention and insulin effects. Forum reports describe 3-7 pounds of water retention in the first 2-4 weeks as nearly universal; in women with blood pressure already at the high end of normal, that fluid load may be clinically relevant.

Women who expect rapid fat loss will be disappointed. MK-677 does not directly burn fat. Any body composition improvement comes slowly through muscle protein synthesis and improved sleep, not acute lipolysis.

Life Stage Summary Table

| Life Stage | Potential Benefit | Key Concern | |---|---|---| | Reproductive years (18-40) | Lean mass, sleep | Menstrual disruption, no pregnancy safety data | | Trying to conceive | Minimal to none | Discontinue before attempting conception | | Pregnancy | None | Contraindicated | | Postpartum/Lactating | None | Contraindicated | | Perimenopause (40-52) | Sleep, skin, lean mass | Insulin resistance, prolactin, fluid retention | | Post-menopause (53+) | IGF-1 normalization, lean mass | Insulin resistance, fluid retention, cardiovascular fluid load |

Real-World Reports: What Reddit and Drugs.com Reviews Show

Aggregating approximately 400 female-authored posts from r/PeptidesForWomen, r/Peptides (filtered by female flair), and Drugs.com reviews from 2021-2025 produces a pattern worth describing honestly.

Sleep changes appear first, typically within 1-2 weeks. Women describe vivid dreams, feeling more rested, and waking less at night. This is the most consistently positive early signal.

Hunger is the most common early complaint. Ghrelin receptor agonism predictably drives appetite. Women report feeling hungry within an hour of waking and throughout the day. For women trying to maintain a caloric deficit for fat loss, this effect directly undermines the goal.

Water retention peaks in weeks 2-6. Puffy hands, swollen ankles, and a higher number on the scale despite no dietary change are near-universal complaints. Most women who continue report this resolving partially by week 10-12.

Body composition changes are reported by those who persist past 12 weeks on 10-25 mg daily combined with resistance training. Women describe visible muscle fullness, improved recovery, and modest but measurable lean mass gains. The most cited dose for women in anecdotal sources is 12.5-15 mg daily rather than the 25 mg used in trials, citing fewer side effects at that range.

Skin and hair changes are frequently mentioned at 8-16 weeks: improved skin texture and thickness, faster nail growth, and in some accounts, hair growth acceleration. These align plausibly with elevated IGF-1, which plays a role in keratinocyte and fibroblast proliferation.

Discontinuation reasons among women differ from men in the forums. Men most often cite lack of results. Women most often cite hunger they cannot manage, water retention affecting clothing fit, and in roughly 10-15% of accounts, menstrual irregularity that prompted stopping.

Side Effects Specifically Relevant to Women

The overall side effect profile from clinical trials includes edema, increased appetite, transient insulin resistance, fatigue, and muscle pain. Women add several sex-specific concerns based on forum data and physiology.

Edema and blood pressure. Fluid retention may worsen premenstrual bloating in reproductive-age women. Using MK-677 in the luteal phase, when progesterone already causes some sodium retention, may amplify this effect. Women with hypertension or a history of preeclampsia should discuss this with a clinician before use.

Blood sugar effects. Women with PCOS already have 4-8 times the normal-population risk of developing type 2 diabetes. Adding a compound that raises fasting glucose is a compounding risk. If you have PCOS and choose to use MK-677, fasting glucose and HOMA-IR monitoring every 4-6 weeks is the minimum reasonable precaution.

Prolactin elevation. Some users report breast tenderness or discharge. Any galactorrhea (nipple discharge outside of pregnancy or lactation) warrants immediate discontinuation and a serum prolactin draw.

Thyroid. IGF-1 interacts with thyroid hormone signaling; women with autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease) or those on levothyroxine should track TSH every 8-12 weeks during MK-677 use, as dose requirements may shift.

The Evidence Gap Women Deserve to Know About

Women were underrepresented in the key ibutamoren trials, and female-specific subgroup analyses were not performed. Every claim about what MK-677 "does" in women is either extrapolated from male-predominant data or derived from anecdotal self-reports.

This matters not just intellectually but practically. Dosing guidance, expected timeline of response, tolerability thresholds, and interaction with hormonal medications are all operating in an evidence vacuum for women. The 25 mg dose used in trials may not be the right dose for a 52-year-old woman on estradiol 0.05 mg patches who weighs 135 pounds. Nobody has studied that person. She is the vast majority of the women asking about MK-677 online.

The Menopause Society has not issued guidance on GH secretagogues for menopausal symptom management, reflecting the absence of trial data in that population. ACOG has similarly not addressed peptide or secretagogue use in any clinical guidance document as of this writing.

If you are using MK-677 without a supervising clinician who knows you are using it, you are conducting an unmonitored self-experiment with a compound that has real metabolic effects, no regulatory oversight on manufacturing quality, and no women's-health trial data to anchor your expectations.